Modular Medical, Inc.

-Seasoned Executive with Proven Track Record in International Pump Launches to Accelerate Global Adoption of User Friendly, Affordable Patch Pumps

-Study to Evaluate Usability and Extended Wear for Next-Generation Tubeless Patch Pump

- Use of MODD1 on clinicians with Type 1 diabetes

-More than 6,000 MODD1 cartridges produced

- Conversion to Pivot-ready manufacturing in preparation for product launch in 1Q26

-Debuting a "coming soon" campaign for tubeless Pivot patch pump

- Expects special 510(k) filing for Pivot product in October

- Will introduce first level of its gamified training application developed by Level Ex, developers of the Level One diabetes-management game

- Use of MODD1 on clinician with Type 1 diabetes

- Modular Medical intends to deploy the MODD1 on a larger number of clinicians in mid August

-Line has been in production at risk since early July
- Production to continue until late August when conversion to Pivot manufacturing will begin

- Engaged BSI Group to start the process of obtaining regulatory clearance of the MODD1, next-generation insulin pump for the European market

- Targeting Q1 2026 for expected clearance of the MODD1 in the E.U.

-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements

-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough

• Meet with Modular Medical CEO, Jeb Besser

• Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association

• About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks

• Discover Modular Medical's Recently Announced Results from a Successful GLP-1 Proof of Concept Study

-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery

- Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone

-Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility

-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024

-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations

-CEO to discuss further details of the program in Tribe Public Webinar on Wednesday, September 11 at 8:30 a.m. Pacific time

• Meet with Modular Medical CEO, Jeb Besser

• There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.

• Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association

• About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks

• MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetes

• Designed to be simpler and more affordable to expand access to diabetes technology for previously underserved communities

• Commercial availability expected in early 2025

Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations